Don’t Forget the Orphans
In: European Journal of Health LawPurchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
3
L.A. Barrera and G.C. Galindo, ‘Ethical aspects on rare diseases’, Adv Exp Med Biol 686 (2010) 493-511.
-
4
J.E. Davies, S. Neidle and D.G. Taylor, ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’, Br J Cancer 106(1) (2012) 14-17.
-
11
G.S. Ginsburg and J.J. McCarthy, ‘Personalized medicine: revolutionizing drug discovery and patient care’, Trends in Biotechnology 19(12) (2001) 491-496.
-
12
M. Herder, ‘When everyone is an orphan: Against adopting a US-styled orphan drug policy in Canada’, Accountability in Research-Policies and Quality Assurance 20(4) (2013) 227-269.
-
14
A. Montserrat Moliner and J. Waligora, ‘The European union policy in the field of rare diseases’, Public Health Genomics 16(6) (2013) 268-277.
-
19
A. Paturel, ‘Too Rare for Research? People with rare diseases often experience significant delays in diagnosis and access to few, if any, treatment options’, Neurology Now 8(2) (2012) 29-33.
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 231 | 30 | 1 |
| Full Text Views | 135 | 5 | 0 |
| PDF Views & Downloads | 19 | 7 | 0 |
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 231 | 30 | 1 |
| Full Text Views | 135 | 5 | 0 |
| PDF Views & Downloads | 19 | 7 | 0 |